US Patent

US12558349 — Methods of treating infections in overweight and obese patients using antibiotics

Method of Use · Assigned to Melinta Subsidiary Corp · Expires 2034-03-14 · 8y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating infections in overweight or obese patients using antibiotics.

USPTO Abstract

The present disclosure relates generally to methods of treating infections in overweight or obese patients using antibiotics.

Drugs covered by this patent

delafloxacin-meglumine (DELAFLOXACIN MEGLUMINE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3967`	—	delafloxacin-meglumine

Patent Metadata

Patent number: US12558349
Jurisdiction: US
Classification: Method of Use
Expires: 2034-03-14
Drug substance claim: No
Drug product claim: No
Assignee: Melinta Subsidiary Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.